RxTrials Institute Drug Pipeline Alert

The FDA has approved Allergan’s Combigan for the reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy.

Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2 percent/0.5 percent is an eye drop that reduces elevated intraocular pressure. It will be available to physicians in the fourth quarter, Allergan said.

Combigan is the newest addition to Allergan's glaucoma portfolio, which includes Lumigan (bimatoprost ophthalmic solution) 0.03 percent and Alphagan P (brimonidine tartrate ophthalmic solution) 0.1 percent and 0.15 percent.